These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18574933)

  • 1. When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
    Huang F; Kavan P; Guiot MC; Markovic Y; Roberge D
    Can J Neurol Sci; 2008 May; 35(2):192-7. PubMed ID: 18574933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
    Newlands ES; Foster T; Zaknoen S
    Br J Cancer; 2003 Jul; 89(2):248-51. PubMed ID: 12865911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
    Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
    J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
    Yung WK; Albright RE; Olson J; Fredericks R; Fink K; Prados MD; Brada M; Spence A; Hohl RJ; Shapiro W; Glantz M; Greenberg H; Selker RG; Vick NA; Rampling R; Friedman H; Phillips P; Bruner J; Yue N; Osoba D; Zaknoen S; Levin VA
    Br J Cancer; 2000 Sep; 83(5):588-93. PubMed ID: 10944597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
    Osoba D; Brada M; Yung WK; Prados M
    J Clin Oncol; 2000 Apr; 18(7):1481-91. PubMed ID: 10735896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
    Brada M; Viviers L; Abson C; Hines F; Britton J; Ashley S; Sardell S; Traish D; Gonsalves A; Wilkins P; Westbury C
    Ann Oncol; 2003 Dec; 14(12):1715-21. PubMed ID: 14630674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
    Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
    Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
    Wick W; Roth P; Hartmann C; Hau P; Nakamura M; Stockhammer F; Sabel MC; Wick A; Koeppen S; Ketter R; Vajkoczy P; Eyupoglu I; Kalff R; Pietsch T; Happold C; Galldiks N; Schmidt-Graf F; Bamberg M; Reifenberger G; Platten M; von Deimling A; Meisner C; Wiestler B; Weller M;
    Neuro Oncol; 2016 Nov; 18(11):1529-1537. PubMed ID: 27370396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
    Silvani A; Lamperti E; Gaviani P; Eoli M; Fiumani A; Salmaggi A; Falcone C; Filippini G; Botturi A; Boiardi A
    J Neurooncol; 2008 Apr; 87(2):143-51. PubMed ID: 17576523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage temozolomide for prior temozolomide responders.
    Franceschi E; Omuro AM; Lassman AB; Demopoulos A; Nolan C; Abrey LE
    Cancer; 2005 Dec; 104(11):2473-6. PubMed ID: 16270316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
    Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
    Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
    Khasraw M; Lee A; McCowatt S; Kerestes Z; Buyse ME; Back M; Kichenadasse G; Ackland S; Wheeler H
    J Neurooncol; 2016 May; 128(1):163-171. PubMed ID: 26935578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial chemotherapy in gliomatosis cerebri.
    Sanson M; Cartalat-Carel S; Taillibert S; Napolitano M; Djafari L; Cougnard J; Gervais H; Laigle F; Carpentier A; Mokhtari K; Taillandier L; Chinot O; Duffau H; Honnorat J; Hoang-Xuan K; Delattre JY;
    Neurology; 2004 Jul; 63(2):270-5. PubMed ID: 15277619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.